CA2576190A1 - Iron chelators for treating radiocontrast-associated renal dysfunction - Google Patents

Iron chelators for treating radiocontrast-associated renal dysfunction Download PDF

Info

Publication number
CA2576190A1
CA2576190A1 CA002576190A CA2576190A CA2576190A1 CA 2576190 A1 CA2576190 A1 CA 2576190A1 CA 002576190 A CA002576190 A CA 002576190A CA 2576190 A CA2576190 A CA 2576190A CA 2576190 A1 CA2576190 A1 CA 2576190A1
Authority
CA
Canada
Prior art keywords
human
injection
contrast agent
iron chelator
renal failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002576190A
Other languages
English (en)
French (fr)
Inventor
Sudhir V. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiva Biomedical LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2576190A1 publication Critical patent/CA2576190A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CA002576190A 2004-08-06 2005-08-05 Iron chelators for treating radiocontrast-associated renal dysfunction Abandoned CA2576190A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59944904P 2004-08-06 2004-08-06
US60/599,449 2004-08-06
PCT/US2005/027712 WO2006017650A2 (en) 2004-08-06 2005-08-05 Iron chelators for treating radiocontrast-associated renal dysfunction

Publications (1)

Publication Number Publication Date
CA2576190A1 true CA2576190A1 (en) 2006-02-16

Family

ID=35539425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002576190A Abandoned CA2576190A1 (en) 2004-08-06 2005-08-05 Iron chelators for treating radiocontrast-associated renal dysfunction

Country Status (6)

Country Link
US (3) US20060127315A1 (https=)
EP (1) EP1776118A2 (https=)
JP (2) JP2008509149A (https=)
AU (1) AU2005271455A1 (https=)
CA (1) CA2576190A1 (https=)
WO (1) WO2006017650A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004507A1 (en) * 2004-10-27 2008-01-03 E-Z-Em, Inc. Data collection device, system, method, and computer program product for collecting data related to the dispensing of contrast media
WO2008057534A2 (en) * 2006-11-07 2008-05-15 University Of Vermont And State Agricultural College Methods and compositions for organ protection
US20080138440A1 (en) * 2006-11-29 2008-06-12 Cormedix Inc. Methods of diagnosing and alleviating gadolinium toxicity
MX2017008959A (es) 2015-01-07 2018-05-17 Nottingham Univ Hospitals Nhs Trust Biomarcadores relacionados con la funcion del riñon y metodos que involucran su uso.
JP2018528207A (ja) * 2015-08-31 2018-09-27 ザ ユニバーシティー オブ アデレード 鉄キレート剤および非鉄ポルフィリンを含む、微生物感染症を予防および／または処置する方法および製品
MD3684344T2 (ro) 2017-10-25 2025-09-30 Chiesi Farm Spa Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1100388A (en) * 1986-12-29 1988-07-27 The Administrators Of The Tulane Eductional Fund Protection against aminoglycoside-induced nephrotoxicity
US5091180A (en) * 1987-11-20 1992-02-25 Administrators Of The Tulane Educational Fund Protection against rhabdomyolysis-induced nephrotoxicity
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
DE60039756D1 (de) * 1999-04-23 2008-09-18 Shiva Biomedical Llc Diagnostisches verfahren für nierenkrankheiten in menschen
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
US6509380B1 (en) * 2001-12-14 2003-01-21 Marshall University Research Corporation Method of treating iron overload with acetaminophen

Also Published As

Publication number Publication date
WO2006017650A3 (en) 2006-11-09
US20080293779A1 (en) 2008-11-27
JP2008509149A (ja) 2008-03-27
US20120053212A1 (en) 2012-03-01
US20060127315A1 (en) 2006-06-15
AU2005271455A1 (en) 2006-02-16
WO2006017650A2 (en) 2006-02-16
EP1776118A2 (en) 2007-04-25
JP2012102110A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
US20120053212A1 (en) Methods of treating humans undergoing injection of a contrast agent
Berg Nephrotoxicity related to contrast media
Bataller et al. Hepatorenal syndrome
Sloand et al. Captopril reduces urinary cystine excretion in cystinuria
Rudnick et al. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial
Rahman et al. Effects of atrial natriuretic peptide in clinical acute renal failure
Ansari et al. Acute renal failure due to radio-contrast agents
Guevara et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
DeFronzo Pathogenesis of glucose intolerance in uremia
JP5116479B2 (ja) オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
Cianciaruso et al. Renal adaptation to dietary sodium restriction in moderate renal failure resulting from chronic glomerular disease.
US7235542B2 (en) Diagnosis and treatment of human kidney diseases
JPWO2008123093A1 (ja) 鉄過剰症の予防または治療剤
US9968626B2 (en) Method for treating obesity
Clark et al. Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days
Vervoort et al. Atrial natriuretic peptide–induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients
Kitamura et al. Tranexamic acid-induced visual impairment in a hemodialysis patient
Simon Detoxification in hemosiderosis
JP2006515348A (ja) 腎不全処置方法
Le Meur et al. Potential nephrotoxicity of intravenous infusions of naftidrofuryl oxalate
Shyh et al. Uninephrectomy does not potentiate contrast media nephrotoxicity in the streptozotocin-induced diabetic rat
JP4925406B2 (ja) 糖尿病性腎症の予防及び／又は治療剤
Satonaka et al. Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis
Reimer Mangafodipir Trisodium “Teslascan”
Nortman et al. Therapy and management of acute renal failure

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130225